Viral protein structure study offers HIV therapy hope
Researchers at NPL have confirmed a definitive structure of an HIV protein, shedding light on its infection mechanism. This discovery may lead to better treatments for people affected by HIV.
Human Immunodeficiency Virus
Articles tagged with Human Immunodeficiency Virus
AIDS drugs given to pregnant women block 99 percent of HIV transmission to breastfed babies
In a groundbreaking study, researchers found that antiretroviral drug combinations given to pregnant and breastfeeding women in Botswana prevented 99% of the mothers from transmitting HIV to their infants. The study's findings have significant implications for maternal health and child survival in developing nations.
Nurses can safely and effectively manage antiretroviral treatment and offer alternative to monitoring by doctors
A randomized trial found that trained nurses can safely and effectively manage antiretroviral treatment, similar to doctor-monitored care. The study adds evidence to the success of 'task-shifting' in HIV care, which could help ease healthcare worker shortages and expand access to ART for millions in need.
Adding nucleic acid testing to HIV screening may help identify more people with HIV
Researchers found that adding nucleic acid testing to HIV screening can detect the presence of HIV earlier, increasing detection yield by 23%. A large majority of study participants received negative test results via automated phone or internet systems. The findings suggest that such programs can help control the HIV epidemic.
Embargoed news from Annals of Internal Medicine
Alzheimer's disease may not be delayed by lifestyle interventions, while a promising medication, diet, exercise, and cognitive engagement show potential benefits. Ribavirin shows promise in treating Chronic Hepatitis E, and adding nucleic acid testing to HIV screening improves case yield.
Directly observed HIV treatment by patient-nominated treatment supporter improves survival
Researchers found that mortality rates were significantly lower among patients who received DOT from a nominated treatment supporter compared to self-monitored ART. The study suggests that social capital and emotional support provided by these supporters contributed to improved survival outcomes.
Insight into structure of HIV protein could aid drug design
The study reveals how HIV protein Tat interacts with the human protein P-TEFb, altering its shape. This knowledge may lead to the design of inhibitors that target P-TEFb only when it is interacting with Tat, potentially reducing viral replication without harming normal cell function.
Snuffing out smoking in those with HIV
The study found that 40-60% of Americans living with HIV/AIDS are smokers, twice the rate in the general population. Researchers emphasize the need for effective interventions to help these individuals quit smoking.
Faith-based groups can aid response to HIV in Central America, study finds
A RAND Corporation study finds that faith-based organizations in Central America can play a crucial role in the HIV response by raising awareness and providing access to healthcare. Researchers recommend building on these groups' existing reach and influence to improve services and support for those affected by the disease.
Scripps research scientists determine structure of immune molecule that counteracts HIV strains
Researchers at Scripps Research Institute have determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus (HIV). The study advances the effort to develop an AIDS vaccine by providing insights into how broadly neutralizing antibodies work.
Many with HIV start care too late
A study of nearly 45,000 patients found that many with HIV in the US and Canada do not receive care early enough, resulting in lower CD4 cell counts. This delay increases the risk of clinical disease progression and ongoing transmission.
Lancet study: Antiretroviral therapy associated with decreased risk of HIV transmission
A large multinational study found that antiretroviral therapy (ART) significantly reduces HIV transmission risk, with 349 HIV-infected partners initiating ART at a rate of 90% HIV transmission reduction. Regular CD4 measurements and counseling services were provided to all couples.
Use of lubricants with anal sex could increase risk of HIV
Research suggests that using lubricants during receptive anal intercourse can increase the risk of rectal sexually transmitted infections (STIs), including HIV. A study involving nearly 900 men and women found that those who used lubricants were three times more likely to have a rectal STI.
IRMA: Research on lubricant safety very past due
New research from the Microbicide Trials Network indicates that some lubricants have toxic effects on cells and rectal tissue. The study's findings support IRMA's calls for safer lubricant options, emphasizing the importance of condom use with compatible lubricants to prevent HIV transmission.
Gene change raises odds of mother-to-child HIV transmission
Researchers found that children born to HIV-positive mothers with specific TLR9 gene variants are at a higher risk of acquiring the virus. The study confirms the relevance of innate immunity in perinatal HIV-1 infection and may lead to new therapeutic strategies.
Microbicides that do more than gel: Vaginal rings, tablets and films
Researchers have developed vaginal rings that can deliver therapeutic levels of two anti-HIV drugs for up to 30 days, while quick-dissolve films and almond-shaped tablets also show potential. These new formulations offer an alternative to daily microbicide gels and could provide a safer and more effective way to prevent HIV transmission.
Vaginal gel with integrase inhibitor shows promise in monkeys
Researchers tested a vaginal microbicide gel containing an integrase inhibitor and found it provided significant protection against infection with a virus similar to HIV. The study showed promise for further evaluation of integrase inhibitors as a potential method for preventing HIV transmission in uninfected individuals.
Scientists see new hope in fight against HIV and TB
New scientific advances offer significant promise for reducing the spread of HIV/AIDS and tuberculosis, including novel TB drugs, rapid diagnostic tests and bold prevention approaches like PrEP. Experts call for policymakers to capitalize on these advances to save millions of lives from these deadly epidemics.
Frequent HIV testing, and early start of antiretroviral treatment in those with HIV, would give short- and long-term declines in TB incidence
Implementing the 3Is policy (Intensified tuberculosis case finding, Infection control, and Isoniazid preventive therapy) combined with earlier start of ART can prevent HIV-associated TB. Early diagnosis and treatment, along with a comprehensive package of HIV care, form the basis of prevention and control of HIV-associated TB.
Tuberculosis: 6 million lives saved so far but the disease still causes 1.8 million deaths worldwide every year
The global burden of tuberculosis remains significant, with 11 million active cases in 2008, despite progress made since the start of DOTS era. Rapid expansion of TB diagnosis and treatment has saved up to six million lives, but further efforts are needed to eliminate the disease by 2050.
Did the end of smallpox vaccination cause the explosive spread of HIV?
Researchers found that vaccinia immunization reduces HIV replication, suggesting it could provide protection against subsequent infection. The decline of smallpox vaccination in the mid-20th century may have led to a loss of this protection, contributing to HIV's rapid contemporary spread.
Frequent alcohol use linked to faster HIV disease progression
A recent study found that frequent alcohol consumption is associated with a faster decline in CD4+ cell counts in individuals with HIV disease. The research, conducted over 30 months, suggests that alcohol has a direct impact on CD4 cells and accelerates immune system decline.
Prescription drug could boost effects of vaccines for HIV and other diseases
A prescription drug, imiquimod, has been found to boost the effectiveness of future vaccines for bacterial and viral diseases like HIV and hepatitis C. Scientists have coated imiquimod with dextran-based microparticles, significantly increasing the efficiency of cellular uptake by immune cells.
New insights into the mystery of natural HIV immunity
Researchers have discovered that individuals with a specific HLA B57 gene carry more potent killer T cells, which can recognize and attack HIV-infected cells. This finding may lead to the development of vaccines that provoke a similar response in people without the gene.
New report confirms fears of people living with HIV: Treatment rationing escalating
The International Treatment Preparedness Group's new report documents early warning signs of devastating impact from global pullback on AIDS commitment and funding. People living with HIV often struggle to afford medicines for opportunistic infections, transport costs, food, and second-line medications.
LA BioMed awarded research grant to study HIV prevention gel
LA BioMed is participating in the international IPM020 study of a dapivirine-containing microbicide gel to evaluate its safety and absorption. The study aims to reduce HIV transmission among women, with the goal of reducing the cycle of infection that has led to millions of deaths worldwide.
Researchers identify the source of 'noise' in HIV
New research identifies the source of 'noise' in HIV gene expression, finding that transcriptional bursting generates exceptionally high levels of noise. This finding suggests that latency may be fundamental to the HIV life cycle.
Latest maternal mortality data show accelerated decreases in China, Egypt, Ecuador and Bolivia, but surprising increases in US, Canada and Denmark
The latest data on maternal mortality show significant progress in reducing deaths in countries like China, Egypt, Ecuador, and Bolivia. However, unexpected increases were found in the US, Canada, and Denmark. The analysis revealed that the number of women dying from pregnancy-related causes has dropped by over 35% globally since 1980.
Maternal deaths fall worldwide from a half-million annually to less that 350,000
The global maternal mortality ratio declined from 422 in 1980 to 320 in 1990 and 251 in 2008, with developing countries making significant progress. The study found that HIV accounts for nearly one out of every five maternal deaths, with six countries accounting for more than half of all maternal deaths.
Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful
A new study found that community-based organizations can effectively implement an evidence-based HIV/STD risk-reduction intervention with adolescents. The intervention increased condom-protected intercourse without reducing the frequency of sexual activity.
Scientists identify how a novel class of antibodies inhibits HIV infection
Researchers at Duke University Medical Center have discovered a set of naturally occurring antibodies that can block HIV's entry into certain blood cells. These polyreactive anti-phospholipid antibodies show promise as a potential new strategy for HIV vaccine design.
Peregrine reports new study from Duke shows anti-HIV potential of targeting PS on cells
Researchers at Duke University found that Peregrine's PS-targeting antibodies can block the CCR5 receptor, a key portal for HIV to gain entry into blood cells. The study showed potent ability to induce specific effects that impact viruses, inducing β-chemokines to block HIV entry.
Caltech scientists uncover structure of key protein in common HIV subgroup
Researchers have uncovered the three-dimensional structure of a key protein found on the surface of a specific HIV-1 subgroup, providing valuable insights for vaccine design. The discovery reveals unusual autoreactivity between an anti-HIV antibody and the CD4 receptor, raising questions about potential autoimmune responses.
Stem cell therapy to tackle HIV
A novel stem cell therapy has been developed to arm the immune system against HIV, potentially improving quality of life and life expectancy for those who have failed antiviral drugs. The therapy involves delivering antiviral DNA to patient immune cells, which can block viral gene production using RNA interference.
Predictors of loss of hepatitis B surface antigen in patients co-infected with HIV and HBV
A study analyzed factors associated with HBsAg loss in HIV-HBV co-infected patients. Higher baseline CD4 cell counts were linked to increased loss of HBsAg, suggesting effective T-cell response against HBV. The research contributes to understanding predictors of HBsAg loss and its implications for management.
UCSF study finds clinic-based HIV prevention is effective in reducing risk behaviors
A UCSF study found that delivering HIV prevention services to people living with HIV in clinical settings can sharply reduce their sexual risk behaviors. The intervention, led by medical care providers during routine visits, resulted in a consistent decline in risky behavior over the 12-month study period.
University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
Researchers have identified BanLec, a lectin in bananas, as an effective anti-HIV agent that can inhibit HIV infection by binding to the sugar-rich HIV-1 envelope protein. This discovery could lead to the development of new microcides to prevent sexual transmission of HIV.
University of Michigan scientists discover bone marrow can harbor HIV-infected cells
Researchers identify a new reservoir for hidden HIV-infected cells in bone marrow, which can serve as a factory for new infections. The discovery opens up new possibilities for treating HIV, particularly for individuals who have been taking anti-viral drugs for their entire life.
How to fortify the immunity of HIV patients
Researchers at Universite de Montreal and VGTI have discovered a new mechanism by which HIV infects immune cells, characterizing the role of two molecules PD-1 and IL-10 in this process. The study suggests that blocking these interactions may restore the immune response in HIV-infected patients.
HIV vaccine strategy expands immune responses
A new HIV vaccine strategy, called 'mosaic vaccines,' has shown promise in expanding immune responses in rhesus monkeys. The approach uses computational methods to create small sets of highly variable artificial viral proteins that stimulate a strong immune response against the diverse forms of HIV.
Injecting drug users have poor access to HIV services
A systematic review found inadequate coverage of effective interventions for HIV prevention among injecting drug users globally. Only 8% of injectors have accessed needle and syringe programs in the last year, with coverage varying greatly between countries.
Combined drug therapy to treat TB and HIV significantly improves survival
A new study published in the New England Journal of Medicine found that initiating antiretroviral therapy during tuberculosis treatment significantly reduces mortality rates for co-infected patients. The trial, which involved 642 patients, showed a 56% reduction in mortality rates compared to those who received sequential therapy.
Increased HAART coverage associated with 50 percent drop in new HIV diagnoses among injection drug users
A comprehensive population-based study by BC-CfE found that increased HAART coverage was associated with a significant decrease in new yearly HIV infections among injection drug users, resulting in improved health outcomes. The initiative aims to expand HIV treatment and care services for hard-to-reach populations.
Penn researchers present Phase II HIV gene therapy trial data at CROI 2010
Researchers from the University of Pennsylvania School of Medicine presented Phase II trial data on Lexgenleucel-T, a cell and gene therapy product for HIV treatment. The study showed 88% of evaluable subjects had a decrease in viral load set point, with one subject maintaining complete control of HIV viremia for over 14 weeks.
Study integrating family planning and HIV treatment funded by the Bill and Melinda Gates Foundation
Researchers aim to improve contraceptive use and reduce unintended pregnancies among HIV-positive women in Kenya. The study, supported by the Bill and Melinda Gates Foundation, will evaluate an integrated model of HIV care and family planning services.
HIV drug resistance lasts about 1 year in women treated with nevirapine to prevent infant infection
A new study confirms that single-dose nevirapine can lead to HIV treatment failure in women, but only if they start full antiretroviral therapy within a year after the dose. The risk of failure decreases significantly after 12 months.
Burden of HIV/TB infections increasingly falling on Hispanic community
A recent study found that the majority of TB-HIV co-infection cases in San Diego are now among Hispanics, highlighting a significant shift in the disease's ethnic makeup. The results emphasize the need for targeted binational prevention efforts to address the widening health disparities.
Scientists discover origin of HIV transmission among male partners
Researchers at the University of California, San Diego, have discovered that HIV RNA in seminal plasma is transmitted during sex, not HIV DNA. This finding has significant implications for developing prevention strategies, including vaccines and microbicides to prevent the spread of sexually transmitted HIV.
Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug
Researchers identified two compounds that bind to novel parts of the HIV protease enzyme, which could improve potency of existing treatments and combat drug-resistant strains. These findings open a new approach to drug design against HIV protease, targeting non-active sites that may help restore effectiveness against resistant superbugs.
New compound could be alternative strategy for preventing HIV infection
Researchers have developed a new compound, EFdA, that is 60,000 times more potent than current HIV therapies and can protect cells for longer periods. This compound has the potential to be used in vaginal gels or creams as an alternative preventative strategy for women whose partners refuse to use condoms.
Control of herpes symptoms does not reduce HIV transmission, international study found
A new study has found that acyclovir, a common medication used to treat herpes symptoms, does not reduce the transmission of HIV. The research, conducted in seven sub-Saharan countries, suggests that frequent genital herpes recurrences can increase HIV levels in the blood and genital tract.
HIV infection prematurely ages the brain
Researchers found HIV reduces brain blood flow even among young patients, accelerating the aging process. Blood flow in HIV brains is comparable to that of uninfected individuals 15-20 years older.
Herpes medication does not reduce risk of HIV transmission, UW-led international study finds
A five-year international study found that acyclovir suppressive therapy did not reduce the risk of HIV transmission in couples where one partner had both HIV and HSV-2. The study revealed significant reductions in plasma HIV levels and genital ulcers, but no impact on HIV transmission.
PrEP treatment prevented HIV transmission in humanized mice
Researchers found that PrEP prevented rectal and intravenous HIV transmission in humanized mice with 90% protection rate. The study suggests PrEP can block multiple routes of HIV transmission, providing a promising approach to prevent new infections.
HIV: Positive lessons from home-based care
A Cochrane Systematic Review found that home-based nursing in HIV/AIDS patients significantly improves self-reported knowledge of HIV, awareness of medications, and self-reported adherence to medication programmes. Home-based care also had a positive impact on HIV stigma, worry, and physical functioning.
Blood fats reduced in HIV patients who switch from lopinavir-ritonavir to raltegravir, but viral supression rate lower in raltegravir patients (SWITCHMRK trials)
A recent study found that HIV patients who switch from lopinavir-ritonavir to raltegravir experience a reduction in blood fat levels, but the rate of viral suppression is lower in the raltegravir group. The results suggest that clinicians need to consider individual patient factors when making treatment decisions.
New ways to pressure HIV
Researchers found that unique reading frames in the HIV genome can induce immune responses, potentially leading to new ways to combat the virus. These findings may prove useful for developing more effective HIV vaccines.
Circumcision associated with significant changes in bacteria
A study published by The Translational Genomics Research Institute found that circumcision significantly alters the bacterial communities of the penis, reducing anaerobic bacteria and increasing aerobic bacteria. This change may contribute to lower HIV risk and protection against bacterial vaginosis in women.
Gladstone scientists identify target that may inhibit HIV infectivity
Researchers at the Gladstone Institutes have discovered surfen, a small molecule that inhibits HIV's ability to bind to cells and enhance infection. The discovery could lead to new treatments for HIV, potentially reducing transmission rates through sexual contact.
UCSF study finds routine HIV screening in community health centers boosts HIV testing
UCSF researchers found that offering rapid HIV tests to patients in community health centers significantly increases the number of patients screened for HIV. The study saw a nearly three-fold increase in screenings from 3,000 to over 11,000 patients.